|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ojima I, Zuniga ES, Berger WT and Seitz
JD: Tumor-targeting drug delivery of new-generation taxoids. Future
Med Chem. 4:33–50. 2012. View Article : Google Scholar :
|
|
4
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schulz TJ, Thierbach R, Voigt A, et al:
Induction of oxidative metabolism by mitochondrial frataxin
inhibits cancer growth: Otto Warburg revisited. J Biol Chem.
281:977–981. 2006. View Article : Google Scholar
|
|
6
|
Zhao Y, Liu H, Riker AI, et al: Emerging
metabolic targets in cancer therapy. Front Biosci (Landmark Ed).
16:1844–1860. 2011. View
Article : Google Scholar
|
|
7
|
Nagasawa H: Pathophysiological response to
hypoxia - from the molecular mechanisms of malady to drug
discovery: drug discovery for targeting the tumor microenvironment.
J Pharmacol Sci. 115:446–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan DA, Sutphin PD, Nguyen P, et al:
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by
chemical synthetic lethality. Sci Transl Med.
3:94ra702011.PubMed/NCBI
|
|
9
|
Warburg O, Posener K and Negelein E: On
metabolism of tumors. Biochem Z. 152:319–344. 1924.(In German).
|
|
10
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ristow M: Oxidative metabolism in cancer
growth. Curr Opin Clin Nutr Metab Care. 9:339–345. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: cancer’s Achilles’ heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horecker BL: The pentose phosphate
pathway. J Biol Chem. 277:47965–47971. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hiatt HH and Horecker BL: D-erythrose
metabolism in a strain of Alcaligenes faecalis. J Bacteriol.
71:649–654. 1956.PubMed/NCBI
|
|
16
|
Batt RD, Dickens F and Williamson DH:
Tetrose metabolism 2. The utilization of tetroses and tetritols by
rat tissues. Biochem J. 77:281–294. 1960.PubMed/NCBI
|
|
17
|
Wang X and Wei Y: Erythrose kill cancer
cell in vitro and inhibit tumor growth in vivo. Cancer Res.
70(Suppl 1): 45482010. View Article : Google Scholar
|
|
18
|
Gou M, Men K, Zhang J, et al: Efficient
inhibition of C-26 colon carcinoma by VSVMP gene delivered by
biodegradable cationic nanogel derived from polyethyleneimine. ACS
Nano. 4:5573–5584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jensen M, Engert A, Weissinger F, et al:
Phase I study of a novel pro-apoptotic drug R-etodolac in patients
with B-cell chronic lymphocytic leukemia. Invest New Drugs.
26:139–149. 2008. View Article : Google Scholar
|
|
21
|
Jansman FG, Sleijfer DT, de Graaf JC,
Coenen JL and Brouwers JR: Management of chemotherapy-induced
adverse effects in the treatment of colorectal cancer. Drug Saf.
24:353–367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Industrial Chemicals Notification
and Assessment Scheme (NICNAS). Full Public Report: Erythrulose
(Erythrulose Pentapharm). http://www.nicnas.gov.au/__data/assets/pdf_file/0015/10338/SN19FR.pdf.
Accessed February 11, 2008
|
|
23
|
Macdonald JS: Toxicity of 5-fluorouracil.
Oncology (Williston Park). 13(7 Suppl 3): 33–34. 1999.
|
|
24
|
Alimonti A, Gelibter A, Pavese I, et al:
New approaches to prevent intestinal toxicity of irinotecan-based
regimens. Cancer Treat Rev. 30:555–562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grothey A: Clinical management of
oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer.
5(Suppl 1): S38–S46. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hotta T, Takifuji K, Arii K, et al:
Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI
regimen for patients with colorectal cancer. Oncol Rep. 14:433–439.
2005.PubMed/NCBI
|
|
27
|
Grenon NN and Chan J: Managing toxicities
associated with colorectal cancer chemotherapy and targeted
therapy: a new guide for nurses. Clin J Oncol Nurs. 13:285–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
